MX341775B - Vectores para vacunas y metodos para potenciar respuestas inmunes. - Google Patents
Vectores para vacunas y metodos para potenciar respuestas inmunes.Info
- Publication number
- MX341775B MX341775B MX2012008506A MX2012008506A MX341775B MX 341775 B MX341775 B MX 341775B MX 2012008506 A MX2012008506 A MX 2012008506A MX 2012008506 A MX2012008506 A MX 2012008506A MX 341775 B MX341775 B MX 341775B
- Authority
- MX
- Mexico
- Prior art keywords
- vaccine vectors
- methods
- immune responses
- enhancing immune
- vaccine
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 5
- 239000013598 vector Substances 0.000 title abstract 5
- 230000028993 immune response Effects 0.000 title abstract 3
- 230000002708 enhancing effect Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000000849 HMGB Proteins Human genes 0.000 abstract 1
- 108010001860 HMGB Proteins Proteins 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6006—Cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29709810P | 2010-01-21 | 2010-01-21 | |
| PCT/US2011/022062 WO2011091255A1 (en) | 2010-01-21 | 2011-01-21 | Vaccine vectors and methods of enhancing immune responses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012008506A MX2012008506A (es) | 2012-11-21 |
| MX341775B true MX341775B (es) | 2016-09-02 |
Family
ID=44307229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012008506A MX341775B (es) | 2010-01-21 | 2011-01-21 | Vectores para vacunas y metodos para potenciar respuestas inmunes. |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8956618B2 (enExample) |
| EP (1) | EP2525817B8 (enExample) |
| JP (3) | JP6242050B2 (enExample) |
| KR (1) | KR101638661B1 (enExample) |
| CN (1) | CN102811734B (enExample) |
| AU (1) | AU2011207331C1 (enExample) |
| CA (1) | CA2787661C (enExample) |
| CL (1) | CL2012002016A1 (enExample) |
| CO (1) | CO6561819A2 (enExample) |
| DK (1) | DK2525817T3 (enExample) |
| EA (1) | EA023058B1 (enExample) |
| ES (1) | ES2643646T3 (enExample) |
| HU (1) | HUE037157T2 (enExample) |
| MX (1) | MX341775B (enExample) |
| NO (1) | NO2525817T3 (enExample) |
| NZ (1) | NZ601609A (enExample) |
| PL (1) | PL2525817T3 (enExample) |
| PT (1) | PT2525817T (enExample) |
| UA (1) | UA110024C2 (enExample) |
| WO (1) | WO2011091255A1 (enExample) |
| ZA (1) | ZA201205824B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3097926B1 (en) * | 2007-11-01 | 2019-10-02 | The Board of Trustees of the University of Arkansas | Compositions and methods of enhancing immune responses to eimeria |
| KR101638661B1 (ko) | 2010-01-21 | 2016-07-11 | 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 | 백신 벡터 및 면역 반응을 강화시키는 방법 |
| PL2579901T3 (pl) | 2010-06-09 | 2020-02-28 | The Board Of Trustees Of The University Of Arkansas | Szczepionka i sposoby ograniczania infekcji campylobacter |
| US20190263888A1 (en) | 2010-10-19 | 2019-08-29 | Op-T Llc | Therapeutic peptides and methods for treating autoimmune related disease |
| EP2646050B1 (en) | 2010-12-02 | 2016-09-07 | mAB-Factory GmbH | Vaccine against influenza h5n1 viruses, medicament and treatment of h5n1 viral infections |
| BR112015019283B1 (pt) * | 2013-02-14 | 2023-12-19 | The Board Of Trustees Of The University Of Arkansas | Composições e métodos de aprimoramento de respostas imunes à eiméria ou infecção por eiméria limitadora |
| MY173901A (en) * | 2013-03-15 | 2020-02-26 | Texas A & M Univ Sys | Compositions and methods of enhancing immune responses to enteric pathogens |
| CN105399808B (zh) * | 2015-11-23 | 2019-05-10 | 青岛农业大学 | 一种许氏平鮋免疫增强蛋白hmgb1基因及编码蛋白和应用 |
| BR112018072592A2 (pt) | 2016-05-03 | 2019-04-16 | The Board Of Trustees Of The University Of Arkansas | vetor de vacina de levedura que inclui polipeptídeos imunoestimulantes e antigênicos, e métodos de uso dos mesmos |
| US11793854B2 (en) | 2019-03-21 | 2023-10-24 | Op-T Llc | Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction |
| WO2021011437A1 (en) | 2019-07-12 | 2021-01-21 | Op-T Llc | Peptides and methods for treating diseases |
| US12048734B2 (en) | 2020-04-17 | 2024-07-30 | Op-T Llc | Bioactive peptides and methods of use thereof |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| US12537071B1 (en) | 2020-07-22 | 2026-01-27 | David Gordon Bermudes | Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU664360B2 (en) | 1991-03-05 | 1995-11-16 | Wellcome Foundation Limited, The | Expression of recombinant proteins in attenuated bacteria |
| EP0897983B1 (en) | 1991-10-25 | 2003-05-07 | Immunex Corporation | Antibody against CD40-L |
| US5981724A (en) | 1991-10-25 | 1999-11-09 | Immunex Corporation | DNA encoding CD40 ligand, a cytokine that binds CD40 |
| US7405270B2 (en) | 1991-10-25 | 2008-07-29 | Immunex Corporation | CD40-Ligand lacking native-pattern glycosylation |
| US5962406A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
| WO1994005326A1 (en) | 1992-09-04 | 1994-03-17 | University Of Saskatchewan | Novel bacterial vaccines using vaccine strains of pathogenic bacteria |
| AU1059095A (en) | 1993-11-24 | 1995-06-13 | Australian National University, The | Treatment of viral disease with cd40l peptide |
| ATE220331T1 (de) | 1995-03-01 | 2002-07-15 | Immunex Corp | Cd40 bindendes protein zur stimulierung der immunantwort |
| DE69631331T2 (de) | 1995-06-07 | 2004-11-18 | Immunex Corp., Seattle | Cd40l mutein |
| US6479258B1 (en) | 1995-12-07 | 2002-11-12 | Diversa Corporation | Non-stochastic generation of genetic vaccines |
| US6713279B1 (en) | 1995-12-07 | 2004-03-30 | Diversa Corporation | Non-stochastic generation of genetic vaccines and enzymes |
| US6306387B1 (en) | 1997-05-29 | 2001-10-23 | The Research Foundation Of State University Of New York | Antigen delivery system |
| US20030045492A1 (en) | 1997-08-13 | 2003-03-06 | Tang De-Chu C. | Vaccination by topical application of recombinant vectors |
| US6969609B1 (en) | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
| CA2223225A1 (en) | 1997-11-28 | 1999-05-28 | Canadian Red Cross Society | Method for inhibiting in vivo immune response |
| AU2004199A (en) | 1997-12-19 | 1999-07-12 | Immunex Corporation | Method for reducing susceptibility to hiv infection |
| GB9806449D0 (en) | 1998-03-25 | 1998-05-27 | Peptide Therapeutics Ltd | Attenuated bacteria useful in vaccines |
| US6190669B1 (en) | 1998-05-13 | 2001-02-20 | University Of Maryland, Baltimore | Attenuated mutants of salmonella which constitutively express the Vi antigen |
| IT1299583B1 (it) | 1998-05-19 | 2000-03-16 | Vander Way Limited | Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica |
| EP1970449B1 (en) | 1998-09-04 | 2010-11-03 | Emergent Product Development UK Limited | Attenuated salmonella SPI2 mutants as antigen carriers |
| US7300774B1 (en) | 1999-12-09 | 2007-11-27 | The Regents Of The University Of California | Multimeric fusion proteins of the TNF superfamily ligands |
| CA2369820A1 (en) | 1999-04-16 | 2000-10-26 | Frank Dicker | Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof |
| EP1067194A1 (en) | 1999-04-16 | 2001-01-10 | F. Hoffmann-La Roche Ag | Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof |
| AU1084901A (en) | 1999-10-14 | 2001-04-23 | Martha S. Hayden-Ledbetter | Dna vaccines encoding antigen linked to a domain that binds cd40 |
| TR200401569T4 (tr) | 1999-12-28 | 2004-07-21 | Akzo Nobel N.V. | Flagelin ya da flagelle'ya karşı antikorların oluşumuna sebep olmayan salmonelle aşısı |
| DE60136334D1 (en) | 2000-02-02 | 2008-12-11 | Us Health | Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff |
| DK1267899T3 (da) | 2000-03-17 | 2005-12-12 | Pharmacia & Upjohn Co Llc | ssa-inaktiverede salmonellavacciner |
| GB0015426D0 (en) | 2000-06-24 | 2000-08-16 | Univ Southampton | Method for generating soluble highly multimeric proteins |
| US20030165538A1 (en) | 2000-06-26 | 2003-09-04 | Maxygen Incorporated | Methods and compositions for developing spore display systems for medicinal and industrial applications |
| AU2002221780A1 (en) | 2000-10-31 | 2002-05-15 | F.Hoffmann-La Roche Ag | Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof |
| US20030060410A1 (en) | 2001-05-15 | 2003-03-27 | North Shore Long Island Jewish Research Institute | Use of HMG fragments as anti-inflammatory agents |
| EP2107110A3 (en) | 2001-05-15 | 2011-10-26 | Ortho-McNeil Pharmaceutical, Inc. | Ex-vivo priming for generating cytotoxic T lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease |
| US7220723B2 (en) | 2001-05-15 | 2007-05-22 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
| ITMI20011986A1 (it) | 2001-09-25 | 2003-03-25 | San Raffaele Centro Fond | Metodo e composizione per l'attivazione di cellule presentanti l'antigene |
| CA2470640A1 (en) | 2001-12-19 | 2003-06-26 | Alcedo Biotech Gmbh | Use of hmgb proteins and nucleic acids that code therefor |
| US6923958B2 (en) | 2002-03-02 | 2005-08-02 | The Scripps Research Institute | DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof |
| EP1499191B1 (en) | 2002-04-15 | 2012-05-09 | Washington University in St. Louis | Regulated attenuation of live vaccines to enhance cross protective immunogenicity |
| US7495090B2 (en) | 2002-05-23 | 2009-02-24 | The Regents Of The University Of California | Nucleic acids encoding chimeric CD154 polypeptides |
| US20060121047A1 (en) | 2002-11-20 | 2006-06-08 | Tracey Kevin J | Use of hmgb polypetides for increasing immune responses |
| US20040141948A1 (en) | 2002-11-20 | 2004-07-22 | Critical Therapeutics, Inc. | Use of HMGB fragments as anti-inflammatory agents |
| US20040156851A1 (en) | 2002-11-20 | 2004-08-12 | Critical Therapeutics, Inc. | HMGB1 combination therapies |
| JP2006510619A (ja) | 2002-11-20 | 2006-03-30 | クリティカル セラピューティクス，インコーポレイテッド | 抗炎症剤としてのｈｍｇｂ断片の使用 |
| US20050181994A1 (en) | 2003-01-06 | 2005-08-18 | Xencor, Inc. | Novel variants of CD40L protein |
| US20060014248A1 (en) | 2003-01-06 | 2006-01-19 | Xencor, Inc. | TNF super family members with altered immunogenicity |
| US7696169B2 (en) | 2003-06-06 | 2010-04-13 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
| US7754209B2 (en) | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
| WO2005025604A2 (en) | 2003-09-10 | 2005-03-24 | The General Hospital Corporation | Use of hmgb and hmgb fragments to decrease specific immune response |
| EP1673389A2 (en) | 2003-10-10 | 2006-06-28 | Xencor Inc. | Novel variants of cd40l protein |
| WO2005058950A2 (en) | 2003-12-11 | 2005-06-30 | Sidney Kimmel Cancer Center | Methods for generating immunity to antigen |
| US8828957B2 (en) | 2003-12-11 | 2014-09-09 | Microvax, Llc | Methods for generating immunity to antigen |
| WO2005103073A2 (en) | 2004-04-27 | 2005-11-03 | Intercell Ag | Td antigens |
| WO2005113598A2 (en) | 2004-05-21 | 2005-12-01 | Xencor, Inc. | Tnf super family members with altered immunogenicity |
| US20080305120A1 (en) * | 2004-06-17 | 2008-12-11 | Medimmune, Inc. | Immunogenic Compositions Comprising Hmgb 1 Polypeptides |
| EP1814576A2 (en) | 2004-07-20 | 2007-08-08 | Critical Therapeutics, Inc. | Combination therapies of hmgb and complement inhibitors against inflammation |
| CN101080487B (zh) | 2004-10-07 | 2012-11-14 | 阿戈斯治疗公司 | 成熟树突细胞组合物及其培养方法 |
| US8513008B2 (en) | 2004-10-07 | 2013-08-20 | Argos Therapeutics, Inc. | Mature dendritic cell compositions and methods for culturing same |
| GB0423681D0 (en) | 2004-10-26 | 2004-11-24 | Sec Dep For Environment Food & | Vaccine and nucleic acids |
| NZ556004A (en) | 2004-12-21 | 2010-05-28 | Vaxinnate Corp | Compositions of influenza viral proteins comprising at least one flagellin and at least one influenza M2 protein |
| WO2006105972A1 (en) | 2005-04-07 | 2006-10-12 | Universite Libre De Bruxelles | Transgenic organism expressing cd40l and uses thereof |
| US20060286074A1 (en) | 2005-05-31 | 2006-12-21 | Yucheng Tang | Methods for immunotherapy of cancer |
| EP1909834A2 (en) | 2005-07-18 | 2008-04-16 | Critical Therapeutics, Inc. | Use of hmgb1 antagonists for the treatment of inflammatory skin conditions |
| DE602006014720D1 (de) | 2005-10-07 | 2010-07-15 | Proyecto Biomedicina Cima Sl | Immunstimulatorische kombination zur vorbeugung und behandlung von hepatitis c |
| JP2009514536A (ja) | 2005-11-07 | 2009-04-09 | シドニー キンメル キャンサー センター | Ｃｄ４０リガンド融合蛋白質ワクチン |
| WO2007054658A1 (en) | 2005-11-14 | 2007-05-18 | King's College London | Control of immune responses |
| WO2007130725A2 (en) * | 2006-02-06 | 2007-11-15 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of hmgb1 for protection against ischemia reperfusion injury |
| WO2007103048A2 (en) | 2006-03-01 | 2007-09-13 | Regents Of The University Of Colorado | Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity |
| WO2007106073A2 (en) | 2006-03-02 | 2007-09-20 | University Of Massachusetts | Modified pathogens for use as vaccines |
| AU2007345768B2 (en) * | 2006-07-27 | 2013-08-01 | Ligocyte Pharmaceuticals, Inc. | Chimeric influenza virus-like particles |
| US8564612B2 (en) * | 2006-08-04 | 2013-10-22 | Apple Inc. | Deep pixel pipeline |
| JP2010500034A (ja) | 2006-08-09 | 2010-01-07 | メッドイミューン バクシーンズ，インコーポレイティド | インフルエンザ赤血球凝集素変異体およびノイラミニダーゼ変異体 |
| CN101522210B (zh) | 2006-09-18 | 2017-03-22 | 阿肯色大学评议会 | 增强免疫应答的组合物和方法 |
| WO2008109825A2 (en) | 2007-03-08 | 2008-09-12 | Mayo Foundation For Medical Education And Research | Inducing immune-mediated tumor cell death |
| CA2688548A1 (en) * | 2007-05-02 | 2009-01-15 | Emory University | Enhancement of glycoprotein incorporation into virus-like particles |
| WO2009059018A1 (en) | 2007-10-30 | 2009-05-07 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to flagellated bacterium |
| EP3097926B1 (en) | 2007-11-01 | 2019-10-02 | The Board of Trustees of the University of Arkansas | Compositions and methods of enhancing immune responses to eimeria |
| KR101638661B1 (ko) | 2010-01-21 | 2016-07-11 | 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 | 백신 벡터 및 면역 반응을 강화시키는 방법 |
| PL2579901T3 (pl) | 2010-06-09 | 2020-02-28 | The Board Of Trustees Of The University Of Arkansas | Szczepionka i sposoby ograniczania infekcji campylobacter |
| AU2012334962B2 (en) | 2011-11-11 | 2017-02-16 | Chr. Hansen A/S | Lactic acid bacteria and their use as dietary supplementals for poultry |
-
2011
- 2011-01-21 KR KR1020127021697A patent/KR101638661B1/ko active Active
- 2011-01-21 PT PT117352302T patent/PT2525817T/pt unknown
- 2011-01-21 UA UAA201210026A patent/UA110024C2/ru unknown
- 2011-01-21 HU HUE11735230A patent/HUE037157T2/hu unknown
- 2011-01-21 US US13/574,504 patent/US8956618B2/en active Active
- 2011-01-21 CA CA2787661A patent/CA2787661C/en active Active
- 2011-01-21 CN CN201180006369.8A patent/CN102811734B/zh active Active
- 2011-01-21 WO PCT/US2011/022062 patent/WO2011091255A1/en not_active Ceased
- 2011-01-21 ES ES11735230.2T patent/ES2643646T3/es active Active
- 2011-01-21 AU AU2011207331A patent/AU2011207331C1/en active Active
- 2011-01-21 EA EA201290675A patent/EA023058B1/ru not_active IP Right Cessation
- 2011-01-21 DK DK11735230.2T patent/DK2525817T3/en active
- 2011-01-21 NZ NZ601609A patent/NZ601609A/en not_active IP Right Cessation
- 2011-01-21 JP JP2012550153A patent/JP6242050B2/ja active Active
- 2011-01-21 PL PL11735230T patent/PL2525817T3/pl unknown
- 2011-01-21 MX MX2012008506A patent/MX341775B/es active IP Right Grant
- 2011-01-21 EP EP11735230.2A patent/EP2525817B8/en active Active
- 2011-01-21 NO NO11735230A patent/NO2525817T3/no unknown
-
2012
- 2012-07-19 CO CO12122137A patent/CO6561819A2/es not_active Application Discontinuation
- 2012-07-20 CL CL2012002016A patent/CL2012002016A1/es unknown
- 2012-08-02 ZA ZA2012/05824A patent/ZA201205824B/en unknown
-
2015
- 2015-02-16 US US14/623,105 patent/US9913893B2/en active Active
-
2016
- 2016-03-08 JP JP2016044306A patent/JP2016117757A/ja active Pending
-
2017
- 2017-12-05 JP JP2017233454A patent/JP6687585B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX341775B (es) | Vectores para vacunas y metodos para potenciar respuestas inmunes. | |
| MX2025009589A (es) | Vacunas a base de peptidos, metodos de fabricacion y sus usos para inducir una respuesta inmune | |
| MX363307B (es) | Plataformas para suministro de antigenos. | |
| NZ597182A (en) | Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response | |
| EP4056198A3 (en) | Outer membrane vesicles | |
| MX2009001412A (es) | Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas. | |
| MX364689B (es) | Vacuna peptidica para prevencion e inmunoterapia de la demencia tipo alzheimer. | |
| WO2014136064A3 (en) | Immunogenic fusion polypeptides | |
| NZ718108A (en) | Neisseria meningitidis compositions and methods thereof | |
| PH12018502403A1 (en) | Hiv vaccine formulation | |
| MX2013001527A (es) | Nuevas vacunas adyuvantes en base a adyuvantes de orientacion para anticuerpos directamente hacia celulas presentadoras de antigenos. | |
| MX2010001054A (es) | Composiciones adyuvantes antigenicas y metodos. | |
| MX2020011781A (es) | Formulacion arn para inmunoterapia. | |
| MX340796B (es) | Composiciones y procedimientos antigenicos del virus respiratorio sincitial. | |
| MY170746A (en) | Parenteral norovirus vaccine formulations | |
| MX2017001638A (es) | Molecula portadora para antigenos. | |
| JP2013518052A5 (enExample) | ||
| MY193519A (en) | Method for decreasing immunogenicity of protein and peptide | |
| WO2013022808A3 (en) | Immunogenic protein conjugates and methods for making and using the same | |
| MX366051B (es) | Composiciones del virus del síndrome reproductor y respiratorio de porcino y sus usos. | |
| PH12015502844B1 (en) | Mammalian milk osteopontin for enhancing immune responsiveness | |
| PH12014501795A1 (en) | Rota virus subunit vaccines and methods of making and use thereof | |
| WO2012174455A3 (en) | Group a streptococcus multivalent vaccine | |
| WO2011038397A3 (en) | Peptide adjuvants, vaccines, and methods of use | |
| WO2013171661A3 (en) | Adjuvant formulations and methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |